Literature DB >> 18209080

Down-regulation of MHC II in mesenchymal stem cells at high IFN-gamma can be partly explained by cytoplasmic retention of CIITA.

Katherine C Tang1, Katarzyna A Trzaska, Sergey V Smirnov, Sergei V Kotenko, Stephan K Schwander, Jerrold J Ellner, Pranela Rameshwar.   

Abstract

Mesenchymal stem cells (MSCs) are located in postnatal bone marrow, show plasticity, are linked to various bone marrow disorders, exhibit phagocytosis, exert Ag-presenting properties (APC), and are immune suppressive. Unlike professional APCs, MSCs respond bimodally to IFN-gamma in MHC-II expression, with expression at 10 U/ml and baseline, and down-regulation at 100 U/ml. The effects at high IFN-gamma could not be explained by down-regulation of its receptor, IFN-gammaRI. In this study, we report on the mechanisms by which IFN-gamma regulates MHC-II expression in MSCs. Gel shift assay and Western blot analyses showed dose-dependent increases in activated STAT-1, indicating responsiveness by IFN-gammaRI. Western blots showed decreased intracellular MHC-II, which could not be explained by decreased transcription of the master regulator CIITA, based on RT-PCR and in situ immunofluorescence. Reporter gene assays with PIII and PIV CIITA promoters indicate constitutive expression of PIII in MSCs and a switch to PIV by IFN-gamma, indicating the presence of factors for effect promoter responses. We explained decreased MHC-II at the level of transcription because CIITA protein was observed in the cytosol and not in nuclei at high IFN-gamma level. The proline/serine/threonine region of CIITA showed significant decrease in phosphorylation at high IFN-gamma levels. An understanding of the bimodal effects could provide insights on bone marrow homeostasis, which could be extrapolated to MSC dysfunction in hematological disorders.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18209080     DOI: 10.4049/jimmunol.180.3.1826

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

1.  Multipotent Mesenchymal Stromal Cells for Autoimmune Diseases.

Authors:  Alan Tyndall
Journal:  Transfus Med Hemother       Date:  2008-07-17       Impact factor: 3.747

Review 2.  Moving from the laboratory bench to patients' bedside: considerations for effective therapy with stem cells.

Authors:  Lauren S Sherman; Jessian Munoz; Shyam A Patel; Meneka A Dave; Ilani Paige; Pranela Rameshwar
Journal:  Clin Transl Sci       Date:  2011-10       Impact factor: 4.689

3.  AMD3100-mediated production of interleukin-1 from mesenchymal stem cells is key to chemosensitivity of breast cancer cells.

Authors:  Steven J Greco; Shyam A Patel; Margarette Bryan; Lillian F Pliner; Debabrata Banerjee; Pranela Rameshwar
Journal:  Am J Cancer Res       Date:  2011-06-25       Impact factor: 6.166

4.  Developmental regulation of TAC1 in peptidergic-induced human mesenchymal stem cells: implication for spinal cord injury in zebrafish.

Authors:  Nitixa Patel; Tilman E Klassert; Steven J Greco; Shyam A Patel; Jessian L Munoz; Bobby Y Reddy; Margarette Bryan; Neil Campbell; Natalia Kokorina; Hatem E Sabaawy; Pranela Rameshwar
Journal:  Stem Cells Dev       Date:  2011-07-26       Impact factor: 3.272

5.  Comparison of immunological characteristics of mesenchymal stem cells derived from human embryonic stem cells and bone marrow.

Authors:  Xin Fu; Yao Chen; Fang-Nan Xie; Ping Dong; Wen-bo Liu; Yilin Cao; Wen-Jie Zhang; Ran Xiao
Journal:  Tissue Eng Part A       Date:  2015-01-08       Impact factor: 3.845

6.  Personalizing Stem Cell Research and Therapy: The Arduous Road Ahead or Missed Opportunity?

Authors:  S A Patel; C C King; P K Lim; U Habiba; M Dave; R Porecha; P Rameshwar
Journal:  Curr Pharmacogenomics Person Med       Date:  2010-03-01

Review 7.  How mesenchymal stem cells interact with tissue immune responses.

Authors:  Yufang Shi; Juanjuan Su; Arthur I Roberts; Peishun Shou; Arnold B Rabson; Guangwen Ren
Journal:  Trends Immunol       Date:  2012-01-07       Impact factor: 16.687

8.  Stem Cell Transplantation for Hematological Malignancies: Prospects for Personalized Medicine and Co-therapy with Mesenchymal Stem Cells.

Authors:  Shyam A Patel; Pranela Rameshwar
Journal:  Curr Pharmacogenomics Person Med       Date:  2011-09-01

Review 9.  The role of recipient T cells in mesenchymal stem cell-based tissue regeneration.

Authors:  Yi Liu; Songlin Wang; Songtao Shi
Journal:  Int J Biochem Cell Biol       Date:  2012-08-09       Impact factor: 5.085

10.  International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials.

Authors:  Jacques Galipeau; Mauro Krampera; John Barrett; Francesco Dazzi; Robert J Deans; Joost DeBruijn; Massimo Dominici; Willem E Fibbe; Adrian P Gee; Jeffery M Gimble; Peiman Hematti; Mickey B C Koh; Katarina LeBlanc; Ivan Martin; Ian K McNiece; Michael Mendicino; Steve Oh; Luis Ortiz; Donald G Phinney; Valerie Planat; Yufang Shi; David F Stroncek; Sowmya Viswanathan; Daniel J Weiss; Luc Sensebe
Journal:  Cytotherapy       Date:  2015-12-23       Impact factor: 5.414

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.